- PTX aims to complete the recruitment of the expansion cohort by the end of 2022
- There have been already two unexpected and stunning responses in the prior cohort of PTX-100 in T-cell lymphomas
- One PTCL patient in previous escalation cohort remains on PTX-100 with durable partial response for 24 months to date
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has announced the opening of enrolment in the expansion cohort of the Phase 1b trial of PTX-100 to treat lymphomas.
Lymphomas refer to a group of aggressive and rare blood cancers with high unmet clinical need.
The expansion will enrol 8 to 12 patients with relapsed and refractory T-cell lymphoma. It is an open-label, non-randomised study led by a world-renowned hematologist, Professor H. Miles Prince, at Epworth hospital in Melbourne.
On back of this news, PTX shares closed 3.3% higher at AU$0.155 on the ASX on 5 April 2022.
Prescient is developing a personalised medicine approach for cancer, including targeted and cellular therapies. PTX-100 is a first-in-class targeted therapy that blocks a vital cancer growth enzyme called GGT-1. It was co-invented by Prescient’s Scientific Founder, Professor Said Sebti, and is exclusively licensed by Prescient from Yale University.
Image source: © Elnur | Megapixl.com
‘Encouraging preliminary evidence’ for PTX-100
The Phase 1b study in patients with T-cell lymphomas demonstrated excellent safety data and encouraging preliminary evidence of clinical efficacy for PTX-100. This prompted clinical investigators to recommend expanding the study and focusing on enrolling patients with T-cell lymphomas (PTCL).
What is Peritoneal T-Cell Lymphoma (PTCL)?
PTCL is a blood cancer with a substantial unmet need for new therapies and PTX believes that this represents an exciting clinical and commercial opportunity for PTX-100. Prescient also plans to include several patients with cutaneous T-cell lymphoma (CTCL). CTCL clinical samples will strengthen insights on drug action in T-cell lymphomas overall.
In both cases, such patients with refractory T-cell lymphomas on standard treatments would typically be anticipated to have disease progression within four months. This signifies the encouraging nature of response to PTX-100.